Theravance Biopharma, Inc. Debt Securities, Available-for-sale, Allowance for Credit Loss
Theravance Biopharma, Inc. (TBPH) had Debt Securities, Available-for-sale, Allowance for Credit Loss of $0 as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Credit Losses › Allowance for Credit Loss
us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss · last filed 2026-08-11
- 2026-06-30: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2026-03-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2025-12-31: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
- 2025-09-30: Debt Securities, Available-for-sale, Allowance for Credit Loss $0.00.
| Period end | Debt Securities, Available-for-sale, Allowance for Credit Loss |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-11 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 |
| 2025-12-31 | $0.00 10-K · filed 2026-03-23 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |